Small cap News

The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

U.S. index futures declined sharply in Tuesday’s pre-market, mirroring the global rout as the U.S.–Israel–Iran conflict fuels a rise in oil prices and renewed inflation worries.

Not only was the cryptocurrency market moving lower, but SPY and QQQ both fell around 2% each in pre-market trade.

Data from Stocktwits showed that retail sentiment on SPY and QQQ turned ‘bearish’.

A Reuters report highlighted rising UK, Canadian and EU interest in Greenland mining, where CRML owns the Tanbreez rare-earth project, one of the world’s largest deposits

Crypto-linked stocks rallied on Monday as Bitcoin climbed toward the $70,000 level.

Investors now await Fed speeches, CrowdStrike and Target earnings, and a week of economic data capped by Friday’s jobs report.

uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.

Data from Stocktwits showed that retail sentiment on SPY has remained ‘bullish’, while it hovered in the ‘bearish’ territory on QQQ.

Retail traders have turned bullish on the infrared optics maker as geopolitical escalation spotlights demand for drone and defense tech.

In post on X, Saylor wrote ‘Turn Of The Century’ pointing to Strategy’s 101th weekly Bitcoin purchase on Monday.

U.S. stock futures slipped late Sunday as escalating U.S.-Iran tensions pushed investors toward safe-haven assets such as Treasuries, gold, and the dollar.

Brokerages see oil trading between $80 and $90 near-term, with prices potentially higher if disruptions persist, while U.S. gasoline may climb toward $3.10- $3.25.

Gold rallied, bonds firmed, and Asian markets declined amid escalating geopolitical tensions in the Middle East, prompting a flight to safe-haven assets.

KORE stated that Searchlight and Abry will acquire all shares of the company’s issued and outstanding common stock that they currently don’t own in an all-cash transaction valued at nearly $726 million.

The company is shifting focus toward SUVs following weaker sedan demand in 2024 and 2025.

Shares of MARA Holdings rose overnight despite the company reporting a loss of over $4 per share, well above the analysts' anticipated loss of $0.03.

U.S. stock futures moved lower late Thursday as Nvidia’s 5.5% post-earnings drop weighed on semiconductor stocks.

The company stated that the “Genius Plan” is a new structured digital asset management strategy, designed to establish a disciplined Bitcoin allocation and capital recycling framework for investors.

Shares of American Bitcoin Corp. jumped as much as10% in pre-market trading following fourth quarter revenue that more than doubled Wall Street’s expectations.

Crypto-linked equities jumped on Wednesday amid Bitcoin’s rally to $69,000 but pared gains as BTC’s price came back down.

The company priced 20 million shares at $5 each, upsized from a previously announced $75 million raise.

Investors assessed Nvidia’s earnings and China commentary alongside broader macro risks.

CASI stated the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.

The company stated that, following the withdrawal of Gilgamesh’s challenge, there are no remaining challenges against its patent.

The company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder.

Chardan cited operational efficiencies and expected margin lift as Lifileucel manufacturing is fully internalized.

Investors will also focus on Nvidia’s earnings, amid closer scrutiny of large-cap technology valuations and rising concerns over hyperscalers’ capital spending on AI.

Blue Hat announced the pricing of its public offering of 32 million units last week, at a price of $0.2 per unit.

The company is on track to initiate the Advanced-3 registrational trial in patients who have not previously received BCG in the second half of 2026.

Traders are now looking ahead to a key Anthropic event on Tuesday, where new product announcements and demonstrations of Claude’s latest features are expected.

The company said its current resources are expected to fund operations into the second quarter of 2028.

The company announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share.

Bitdeer said on Monday that it plans to keep mining Bitcoin and anticipates that its hash rate will continue to grow.

The Fear and Greed Index flashed a reading of ‘5’ within the ‘Extreme Fear’ territory on Sunday night, a second time this month since February 5.

The surge comes as CEO William Li targets profitability in Nio’s power business, with plans to add 1,000 new swap stations in 2026.

Investors are now headed for a catalyst-heavy week, led by Nvidia and Salesforce earnings, U.S. labor and inflation data, and a busy slate of Federal Reserve speakers.

In the wake of Blue Owl’s redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

Traders are closely watching positioning, as short interest hit a record 13.7% of the free float amid a jump in retail activity on Stocktwits this week.

Investors will monitor the first Q4 U.S. economic growth report, covering a period that included the longest federal government shutdown on record.

Candel is pushing ahead with an equity raise and also lined up $100 million in royalty funding from RTW Investments, contingent on FDA approval of CAN-2409.

The company expects full-year gold production of 820,000 to 970,000 ounces.

The company said that if approved, Bysanti could be available for sale in the U.S. this year.

The standoff ended when the EU granted conditional approval, sending shares up 42% on Wednesday.

Traders looked ahead to U.S. jobless claims, Fed speakers, and other economic data due Thursday.

The company stated that while it cannot disclose the specifics of the order, it will deliver it in its entirety in 2026.

The company forecast fiscal year 2026 revenue of $380 million to $420 million, missing the consensus estimate of $456 million, according to TheFly.

The company is planning to seek FDA guidance on a rolling review and target a New Drug Application submission in the fourth quarter.

Peter Thiel's Founder Fund previously disclosed a 7.5% stake in August following the company’s pivot to an Ethereum treasury strategy.

Koyfin data shows an average 12-month target of $11.8, implying a 96% upside from the stock's current levels.